In order to boost T cell responses against cancer cells, combinations of two checkpoint inhibitors (Durvalumab and Tremelimumab) targeting the CTLA-4 and PD-1/PDL-1 axes have been evaluated [231,232]. Here, PDCD1 is linked to cancer.